Comparative efficacy of various thrombolytic agents in treatment of pulmonary embolism
The authors carried out a retrospective analysis of clinical efficacy of streptokinase and alteplase (actilyse®) in patients presenting with high- and intermediate-to-high risk pulmonary artery thromboembolism (PATE) who were discharged from hospital after appropriate treatment performed. Of the total number of the treated patients, we formed 2 groups comprising 20 patients each, receiving alteplase (group 1) and streptokinase (group 2). The patients were comparable by the main clinical characteristics, predisposing factors, severity of pulmonary artery thromboembolism (PATE) and duration of treatment. Efficacy of thrombolytic therapy assessed clinically and instrumentally did not differ. However, by the stratified risk and frequency of PATE relapses, the condition of patients receiving alteplase turned out to be more severe. Based on the obtained results, a conclusion was made that actilyse is a drug of choice for treatment of patients with PATE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery - 25(2019), 3 vom: 10., Seite 23-28 |
| Sprache: |
Russisch |
|---|
| Weiterer Titel: |
Sravnitel'naia éffektivnost' razlichnykh tromboliticheskikh preparatov v lechenii tromboémbolii legochnoĭ arterii |
|---|
| Beteiligte Personen: |
Khorev, N G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Actilyse |
|---|
| Anmerkungen: |
Date Completed 07.11.2019 Date Revised 31.07.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.33529/ANGI02019316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301120501 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301120501 | ||
| 003 | DE-627 | ||
| 005 | 20231225103954.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.33529/ANGI02019316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1003.xml |
| 035 | |a (DE-627)NLM301120501 | ||
| 035 | |a (NLM)31503244 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Khorev, N G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative efficacy of various thrombolytic agents in treatment of pulmonary embolism |
| 246 | 3 | 3 | |a Sravnitel'naia éffektivnost' razlichnykh tromboliticheskikh preparatov v lechenii tromboémbolii legochnoĭ arterii |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2019 | ||
| 500 | |a Date Revised 31.07.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The authors carried out a retrospective analysis of clinical efficacy of streptokinase and alteplase (actilyse®) in patients presenting with high- and intermediate-to-high risk pulmonary artery thromboembolism (PATE) who were discharged from hospital after appropriate treatment performed. Of the total number of the treated patients, we formed 2 groups comprising 20 patients each, receiving alteplase (group 1) and streptokinase (group 2). The patients were comparable by the main clinical characteristics, predisposing factors, severity of pulmonary artery thromboembolism (PATE) and duration of treatment. Efficacy of thrombolytic therapy assessed clinically and instrumentally did not differ. However, by the stratified risk and frequency of PATE relapses, the condition of patients receiving alteplase turned out to be more severe. Based on the obtained results, a conclusion was made that actilyse is a drug of choice for treatment of patients with PATE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a actilyse | |
| 650 | 4 | |a pulmonary artery thromboembolism | |
| 650 | 4 | |a streptokinase | |
| 650 | 4 | |a thrombolysis | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 700 | 1 | |a Beller, A V |e verfasserin |4 aut | |
| 700 | 1 | |a Borovikov, É V |e verfasserin |4 aut | |
| 700 | 1 | |a Kon'kova, V O |e verfasserin |4 aut | |
| 700 | 1 | |a Shoĭkhet, Ia N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery |d 1998 |g 25(2019), 3 vom: 10., Seite 23-28 |w (DE-627)NLM095450270 |x 1027-6661 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:3 |g day:10 |g pages:23-28 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.33529/ANGI02019316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2019 |e 3 |b 10 |h 23-28 | ||